Microbial degradation of linear peptides by strain B-9 of Sphingosinicella and its application in peptide quantification using liquid chromatography-mass spectrometry

Miyachi, Atsushi; Kondo, Fumio; Kurita, Miki; Tsuji, Kiyomi; Harada, Kenichi

doi:10.1016/j.jbiosc.2014.10.029

Cited by 5 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, we confirmed that one of the B-9 proteases (presumed to be MlrB), which is not inhibited by EDTA, cleaved bioactive peptides in the manner of an endopeptidase similar to NEP. Another protease, which is not inhibited by PMSF, corresponded to MlrC and cleaved the resulting middle-sized peptides to smaller peptides or amino acids [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Strain B-9 degrades MC-LR, the most toxic of the MCs, within 24 h [ 14 , 15 ]. After the discovery of strain B-9, we advanced our research on the degradation of the following compounds: non-toxic cyanobacterial cyclic peptides that are structurally different from MCs [ 16 ]; representative cyclic peptides (antibiotics) produced by bacteria [ 17 ]; physiologically-active cardiovascular and neuropeptides [ 18 ]; and the glucagon/vasoactive intestinal polypeptide (VIP) family of peptides [ 19 ]. The aforementioned experiments [ 17 , 18 , 19 ] confirmed that strain B-9 could degrade the tested peptides completely.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Microbial Degradation of Amino Acid-Containing Compounds Using the Microcystin-Degrading Bacterial Strain B-9

et al. 2018

Self Cite

View full text Add to dashboard Cite

Strain B-9, which has a 99% similarity to Sphingosinicella microcystinivorans strain Y2, is a Gram-negative bacterium with potential for use in the degradation of microcystin-related compounds and nodularin. We attempted to extend the application area of strain B-9 and applied it to mycotoxins produced by fungi. Among the tested mycotoxins, only ochratoxin A was completely hydrolyzed to provide the constituents ochratoxin α and l-phenylalanine, and levels of fumonisin B1 gradually decreased after 96 h. However, although drugs including antibiotics released into the aquatic environment were applied for microbial degradation using strain B-9, no degradation occurred. These results suggest that strain B-9 can only degrade amino acid-containing compounds. As expected, the tested compounds with amide and ester bonds, such as 3,4-dimethyl hippuric acid and 4-benzyl aspartate, were readily hydrolyzed by strain B-9, although the sulfonamides remained unchanged. The ester compounds were characteristically and rapidly hydrolyzed as soon as they came into contact with strain B-9. Furthermore, the degradation of amide and ester compounds with amino acids was not inhibited by the addition of ethylenediaminetetraacetic acid (EDTA), indicating that the responsible enzyme was not MlrC. These results suggest that strain B-9 possesses an additional hydrolytic enzyme that should be designated as MlrE, as well as an esterase.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Microbial Degradation of Amino Acid-Containing Compounds Using the Microcystin-Degrading Bacterial Strain B-9

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…HbA1c measured in Japan Diabetes Society (JDS) units was converted to NGSP units using the following formula: NGSP (%)=1.02*JDS (%)+0.25 12. GLP-1 and GIP measured in pg/mL were converted to pmol/L using the following formulas: GLP-1 (pmol/L)=GLP-1 (pg/mL) /3297.6×1000; GIP (pmol/L)=GIP (pg/mL) /4983.5×1000 13…”

Section: Methodsmentioning

confidence: 99%

“…12 GLP-1 and GIP measured in pg/mL were converted to pmol/L using the following formulas: GLP-1 (pmol/L)=GLP-1 (pg/mL) /3297.6×1000; GIP (pmol/L)=GIP (pg/ mL) /4983.5×1000. 13 All MDs and 95% CIs used absolute changes not relative changes.…”

Section: Assessment Of the Risk Of Bias Of Included Studiesmentioning

confidence: 99%

Efficacy of a meal sequence in patients with type 2 diabetes: a systematic review and meta-analysis

Okami

Tsunoda

Watanabe

et al. 2022

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionThis systematic review investigated the efficacy of a meal sequence, the carbohydrate-later meal pattern (CL), on type 2 diabetes mellitus (T2DM).Research design and methodsWe searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov until April 2020 to perform meta‐analyses using random-effects models. Primary outcomes were hemoglobin A1c (HbA1c) and quality of life. Secondary outcomes were plasma concentrations of glucose, insulin and incretin 120 min after a meal, and any adverse outcomes. The revised Cochrane risk-of-bias tool and Grading of Recommendations, Assessment, Development, and Evaluation approach were used to assess the quality of individual studies and the body of evidence, respectively. The present study was registered in the UMIN Clinical Trials Registry.ResultsWe included 230 participants in eight trials, including both trials that examined long-term changes (more than 2 months and less than 2 years) and short-term changes (in 2-hour postprandial values). CL resulted in a slight to no difference in HbA1c (mean difference (MD), −0.21% in the intervention group; 95% CI −0.44% to+0.03%), plasma glucose (MD,+4.94 mg/dL; 95% CI −8.34 mg/dL to +18.22 mg/dL), plasma insulin (MD, −3.63 μIU/mL; 95% CI −11.88 μIU/mL to +4.61 μIU/mL), plasma GLP-1 (MD, +0.43 pmol/L; 95% CI −0.69 pmol/L to +1.56 pmol/L), and plasma GIP (MD, −2.02 pmol/L; 95% CI −12.34 pmol/L to +8.31 pmol/L). All of these outcomes were of low-certainty evidence or very low-certainty evidence. None of the trials evaluated quality of life or adverse events.ConclusionsThere was no evidence for the potential efficacy of recommending CL beyond standard dietary advice on T2DM.Trial registration numberUMIN000039979.

show abstract

“…The mlrA and mlrD genes are located between mlrC and mlrB , in which mlrA and mlrC encode a metallopeptidase, mlrB encodes a serine protease, and mlrD encodes a putative transporter protein ( 4 ). These enzymes are also responsible for the degradation of many physiologically active peptides ( 6 – 8 ) in addition to the hepatotoxic nodularin and nontoxic aeruginopeptin ( 9 , 10 ). To identify the construction of the microcystin-degrading gene, Okano et al ( 11 ) reported the whole-genome sequence of the microcystin-degrading bacterium Sphingopyxis sp.…”

Section: Announcementmentioning

confidence: 99%

Complete Genome Sequence of a Microcystin-Degrading Bacterium, Sphingosinicella microcystinivorans Strain B-9

Jin

Nishizawa

Guo

et al. 2018

Microbiol Resour Announc

Self Cite

View full text Add to dashboard Cite

show abstract

Microbial degradation of linear peptides by strain B-9 of Sphingosinicella and its application in peptide quantification using liquid chromatography-mass spectrometry

Cited by 5 publications

References 23 publications

Microbial Degradation of Amino Acid-Containing Compounds Using the Microcystin-Degrading Bacterial Strain B-9

Microbial Degradation of Amino Acid-Containing Compounds Using the Microcystin-Degrading Bacterial Strain B-9

Efficacy of a meal sequence in patients with type 2 diabetes: a systematic review and meta-analysis

Complete Genome Sequence of a Microcystin-Degrading Bacterium, Sphingosinicella microcystinivorans Strain B-9

Contact Info

Product

Resources

About